T-cell therapy for KRAS G12V solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a metastatic solid tumor with a KRAS G12V mutation.
- Your immune type is HLA-A*11:01 (a blood test will confirm this).
- You have at least one tumor that can be measured on a scan.
- You are 18 or older and willing to undergo leukapheresis (a procedure to collect your white blood cells).
- You have tried at least one prior treatment, and your cancer has grown or you could not tolerate it.
- Your kidney, liver, heart, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This trial tests a new cell therapy (TCR-T) designed to target KRAS mutations in advanced cancers. It is for people whose standard treatments have stopped working.
This trial tests a new kind of treatment that uses your own immune cells (T cells) that are specially trained to find and attack cancer cells that have a KRAS G12D mutation. It's for people with advanced solid tumors that haven't been helped by standard treatments.
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Hear when a new Metastatic Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.